期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤治疗进展及其对预后的影响 被引量：1

原文传递
导出
摘要 多发性骨髓瘤(MM)是浆细胞恶性肿瘤,好发于中老年人,其发病率居血液系统恶性肿瘤的第二位,约占血液系统恶性肿瘤的10%[1]。特征是骨髓中浆细胞克隆性增生积聚并分泌M蛋白,表现为溶骨性病变或骨质疏松及贫血、感染、肾功能损害等临床表现[2]。MM近年来发病率呈现逐步上升趋势,传统化疗的中位生存期不超过3年。约25%的患者能存活5年以上,存活10年的MM患者不到5%,
作者 沈君 王开泰
机构地区 上海市第一人民医院宝山分院血液科
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2015年第S1期166-169,共4页 Chinese Journal of Practical Internal Medicine
关键词 多发性骨髓瘤 治疗 预后 multiple myeloma treatment prognosis
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Stephen J Russell,S Vincent Rajkumar.Multiple myeloma and the road to personalised medicine[J]. Lancet Oncology . 2011 (7)
  • 2Sonia Vallet,Antonio Palumbo,Noopur Raje,Mario Boccadoro,Kenneth C. Anderson.Thalidomide and lenalidomide: Mechanism-based potential drug combinations[J]. Leukemia & Lymphoma . 2008 (7)
  • 3Antonio Palumbo,Sara Bringhen,Tommaso Caravita,Emanuela Merla,Vincenzo Capparella,Vincenzo Callea,Clotilde Cangialosi,Mariella Grasso,Fausto Rossini,Monica Galli,Lucio Catalano,Elena Zamagni,Maria Teresa Petrucci,Valerio De Stefano,Manuela Ceccarelli,Maria Teresa Ambrosini,Ilaria Avonto,Patrizia Falco,Giovannino Ciccone,Anna Marina Liberati,Pellegrino Musto,Mario Boccadoro.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial[J]. The Lancet . 2006 (9513)
  • 4Brett T.Brinker,Edmund K.Waller,TraciLeong,Leonard T.Heffner, Jr.,IstvanRedei,Amelia A.Langston,SagarLonial.Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma[J]. Cancer . 2006 (10)
  • 5HaniHassoun,LilianReich,Virginia M.Klimek,MadhavDhodapkar,AdamCohen,TarunKewalramani,RachelZimman,LisaDrake,Elyn R.Riedel,Cyrus V.Hedvat,JulieTeruya‐Feldstein,Daniel A.Filippa,MartinFleisher,Stephen D.Nimer,Raymond L.Comenzo.Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma[J]. British Journal of Haematology . 2005 (2)
  • 6Sonneveld P,Schmidt-Wolf IGH,Van der Holt B, et al.HOVON-65/GMMG-HD4 Randomized phase Ⅲtrial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high dose melphalan and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma. Blood . 2010
  • 7Niesvizky R,Flinn IW,Rifkin RM,et al.Phase 3b UPFRONT Study:safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly,newly diagnosed multiple myeloma patients. Blood . 2010
  • 8Spencer,A.,Prince,M.,Roberts,A.W.First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6) [abstract]. Blood . 2006
  • 9Palumbo Antonio,Hajek Roman,Delforge Michel,Kropff Martin,Petrucci Maria Teresa,Catalano John,Gisslinger Heinz,Wiktor-J?drzejczak Wies?aw,Zodelava Mamia,Weisel Katja,Cascavilla Nicola,Iosava Genadi,Cavo Michele,Kloczko Janusz,Bladé Joan,Be.Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England Quarterly . 2012
  • 10Attal Michel,Lauwers-Cances Valerie,Marit Gerald,Caillot Denis,Moreau Philippe,Facon Thierry,Stoppa Anne Marie,Hulin Cyrille,Benboubker Lofti,Garderet Laurent,Decaux Olivier,Leyvraz Serge,Vekemans Marie-Christiane,Voillat Laurent,Michallet M.Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England Quarterly . 2012

同被引文献5

引证文献1

二级引证文献6

中国实用内科杂志
2015年 第S1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部